DeepSecMS Advances DIA‐Based Selenoproteome Profiling Through Cys‐to‐Sec Proxy Training
Advanced Science · 2025
DOI: 10.1002/advs.202504109 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Chenfang Si und 5 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 100 Haike Rd., Shan…. Hauptthemen laut MEDLINE: Selenoproteins, Selenocysteine, Proteomics, Proteome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shanghai, Shanghai Municipal Science and Technology Major Project.
Abstract (Originalsprache)
Selenoproteins, defined as proteins containing the 21st amino acid, selenocysteine (Sec, U), are functionally important but rare, with only 25 selenoproteins characterized in the entire human proteome to date. To comprehensively analyze selenoproteomes, previously developed selenocysteine‐specific mass spectrometry (SecMS) and the selenocysteine insertion sequence (SECIS)‐independent selenoprotein database (SIS) have provided effective tools for analyzing the selenoproteome and, more importantly, hold the potential to uncover new selenoproteins. In this study, a deep learning approach is employed to develop the DeepSecMS method. Given the rarity of Sec and its chemical similarity to cysteine (Cys, C), a proxy training strategy is utilized using a large dataset of Cys‐containing peptides to generate a large‐scale theoretical library of Sec‐containing peptides. It is shown that DeepSecMS enables the accurate prediction of critical features of Sec‐containing peptides, including MS2, retention time (RT), and ion mobility (IM). By integrating DeepSecMS with data‐independent acquisition (DIA) methods, the identification of known selenoproteins is significantly enhanced across diverse cell types and tissues. More importantly, it facilitates the identification of numerous highly scored, potential novel selenoproteins. These findings highlight the powerful potential of DeepSecMS in advancing selenoprotein research. Moreover, the proxy training strategy may be extended to the analysis of other rare post‐translational modifications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 100 Haike Rd., Shanghai, 201210, China.
- University of Chinese Academy of Sciences, Beijing, 100049, China.
- Department of Chemistry, Fudan University, Shanghai, 200000, China.
- Center for Infectious Disease Research & School of Engineering, Westlake University, Hangzhou, 310024, China.
- Shanghai Key Laboratory of Aging Studies, Chinese Academy of Sciences, 100 Haike Rd., Shanghai, 201210, China.
ORCID-Profile: Yaoyang Zhang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shanghai
- Shanghai Municipal Science and Technology Major Project
- Shanghai Basic Research Pioneer Project
- Shanghai Key Laboratory of Aging Studies
- Natural Science Foundation of Shanghai Municipality
Zitieren
APA
Si, C., Yuan, Y., Zong, Y., Qiao, L., Zeng, W. F., & Zhang, Y. (2025). DeepSecMS Advances DIA‐Based Selenoproteome Profiling Through Cys‐to‐Sec Proxy Training. Advanced Science. https://doi.org/10.1002/advs.202504109
Vancouver
Si C, Yuan Y, Zong Y, Qiao L, Zeng WF, Zhang Y. DeepSecMS Advances DIA‐Based Selenoproteome Profiling Through Cys‐to‐Sec Proxy Training. Advanced Science. 2025. doi:10.1002/advs.202504109
BibTeX
@article{Si2025,
author = {Si, Chenfang and Yuan, Yamei and Zong, Yu and Qiao, Liang and Zeng, Wen-Feng and Zhang, Yaoyang},
title = {DeepSecMS Advances DIA‐Based Selenoproteome Profiling Through Cys‐to‐Sec Proxy Training},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202504109}
}
EUVIMED